Dr. Kopans criticizes me and others for being “unable to break free of doubts” about the efficacy of mammography and says those who suggest there is ambiguity in its benefit are using “unscientific data analyses” and “scientifically unsupportable” data that have “been manipulated to generate doubt.”
Dr. Kopans criticizes me and others for being “unable to break free of doubts” about the efficacy of mammography and says those who suggest there is ambiguity in its benefit are using “unscientific data analyses” and “scientifically unsupportable” data that have “been manipulated to generate doubt.”
Despite these assertions, there are credible questions about mammography. Just this year there have been a plethora of articles in various medical journals that highlight such potential downsides of screening mammography as overdiagnosis. As Dartmouth professor H. Gilbert Welch wrote in a British Medical Journal editorial this past July, overdiagnosis is a “vexing problem,” and causes some women to undergo unnecessary treatment. Welch, however, does not disparage mammography; instead, he writes, “Mammography is one of medicine's 'close calls'-a delicate balance between benefits and harms-where different people in the same situation might reasonably make different choices. Mammography undoubtedly helps some women but hurts others. No right answer exists; instead it is a personal choice.”
As I wrote in my April 2009 Diagnostic Imaging article, I believe there is sufficient, albeit not incontrovertible, evidence that mammography does reduce mortality from breast cancer, and that radiologists and other physicians should, after discussing both the pros and the cons of screening, encourage but not coerce women to undergo annual screening mammography. At the same time, however, acknowledging rather than denying the existence of controversies regarding mammography will assist the public at large to develop a realistic appraisal of mammography's role with regard to breast cancer.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
2 Commerce Drive
Cranbury, NJ 08512